ABBVIE INC. vs. Amneal Pharmaceuticals, Inc. Class A Common Stock
ABBV
ABBVIE INC.
$264.47 +0.17%
VS AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock
$17.01 +0.83%
ABBVIE INC. (ABBV) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| ABBV | AMRX | |
|---|---|---|
| Market Cap | $466.55 billion | $5.92 billion |
| Revenue (TTM) | $64.39 billion | $3.12 billion |
| Net Income (TTM) | $6.32 billion | $215.32 million |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | AMRX | |
|---|---|---|
| P/E Ratio | 74.71 | 34.71 |
| Price / Book | -79.24 | 179.40 |
| Price / Sales | 7.25 | 1.90 |
AMRX leads on 2 of 3 valuation factors.
Profitability
| ABBV | AMRX | |
|---|---|---|
| Net Margin | 9.81% | 6.91% |
| Return on Equity | -107.29% | 652.01% |
ABBV and AMRX split the profitability factors evenly.
Dividend
| ABBV | AMRX | |
|---|---|---|
| Dividend Yield | 2.62% | — |
| Payout Ratio | 195.48 | — |
ABBV and AMRX split the dividend factors evenly.
Risk & Sentiment
| ABBV | AMRX | |
|---|---|---|
| Short Interest | 0.85% | 2.39% |
ABBV leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, AMRX overview, AMRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.